Zymeworks's EPS (Basic) for the
three
months ended in Dec. 2023 was $-0.19.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.72.
Zymeworks's EPS without NRI for the
three
months ended in Dec. 2023 was $-0.18.
Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.72.
During the past 12 months, Zymeworks's average EPS without NRIGrowth Rate was -190.40% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 22.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 10 years, Zymeworks's highest 3-Year average EPS without NRI Growth Rate was 22.10% per year. The lowest was -82.10% per year. And the median was -18.55% per year.
Zymeworks EPS (Diluted) Historical Data
The historical data trend for Zymeworks's EPS (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Zymeworks's EPS (Diluted)
For the Biotechnology subindustry, Zymeworks's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zymeworks's PE Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zymeworks's PE Ratio distribution charts can be found below:
* The bar in red indicates where Zymeworks's PE Ratio falls into.
Zymeworks EPS (Diluted) Calculation
EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.
Zymeworks's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as
EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.73
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zymeworks (NAS:ZYME) EPS (Diluted) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Zymeworks EPS (Diluted) Related Terms
Thank you for viewing the detailed overview of Zymeworks's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ZYME has been successfully added to your 